Proscia to Transform the Clinical Use of Digital Pathology in Commercial and Hospital Labs
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 2 minutes
Built from its award-winning software platform, Proscia’s new offering leverages machine learning and artificial intelligence (AI) techniques, leading the move towards precision medicine and computational pathology. Proscia now provides hospital, academic, and commercial labs a digital platform for generating additional revenue and improving workflow efficiency, while driving accuracy and increased confidence in results that benefits both pathologists and patients.
“Proscia’s new clinical solutions are exciting, as they give us the flexibility to adopt digital pathology in phases and set us on a course to incorporate Proscia’s AI-based computational pathology applications,” said Dr. Nicolas Cacciabeve, Managing Director of Advanced Pathology Associates, a 15-pathologist independent practice providing service to seven hospitals and an anatomic pathology reference laboratory in the Rockville, Maryland area. “The application of digital pathology in our practice will transform both the economics and profits of our practice and most importantly improve patient outcomes.”
Proscia’s newly released clinical offering is the next major step in the company’s evolution, focusing on improving clinical workflow and providing pathologists with powerful software and applications for a wide range of non-primary diagnostic clinical uses in a case-centric workflow.*
Commercial and medical facility users of Proscia’s new clinical offering gain access to a broad range of capabilities within a single, unified, platform, including:
• Modular adoption of digital pathology, for those clients who choose to incrementally adopt digital pathology
• An online, role-based consultation portal
• Automated quantitative immunohistochemistry (IHC)
• Image analysis
• Image and case management with configurable workflows
• HIPAA compliant infrastructure
• LIS integration
• Flexible deployment options in the cloud or on-prem
• Vendor-agnostic scanner support
“Labs have been adopting digital solutions incrementally over the past five to ten years, furthering the regulatory and economic incentives to go digital,” said David West Jr., co-founder and chief executive officer of Proscia. “Proscia’s clinical offering is released at a time of growing enthusiasm around clinical applications for digital pathology. Our new release provides our customers with new opportunities to expand the reach and expertise of their existing practices while building a launch-pad for the next generation of precision medicine and analytic tools for pathology automation and augmentation through computational pathology.”
Computational pathology offers an opportunity to combine the Whole Slide Images of digital pathology with other sources of data – such as LIMS, EMR, laboratory data (“-omics”), and radiology images, and then apply AI-based algorithms to provide pathologists with a more complete, computer-assisted view of the disease processes present in a tissue sample. Such algorithms can identify complex histological patterns like tumors, classify cancer subtypes, and even predict outcomes with a high degree of accuracy. These building block capabilities can be deployed in pathology workflows for precision screening, automated triaging, and used as image-based assays as corollaries or in complement with their molecular counterparts.
Join Proscia’s webinar, “Pathology is going digital. Is your lab ready?”, on October 19th to learn more.
Proscia’s new computational pathology platform has caught the imagination of a broad ecosystem as a best-in-class solution to both augment the work of pathologists and dramatically improve patient outcomes.
NVIDIA is another technology company taking notice of the impact that Proscia is having on pathology. “AI is changing the healthcare landscape and pathology is one area that could benefit greatly,” said Abdul Hamid Halabi, Global Business Development Lead, Healthcare & Life Sciences at NVIDIA. “Proscia is building a leading platform to leverage AI for pathology with the goal of not only helping physicians become more efficient, but also to give them the ability to innovate beyond the limits of current pathology tools.”
“Pathology is at an inflection point and the shift to digital is now a strategic initiative for anatomic pathology labs,” said Patrick Myles, CEO at Huron Digital Pathology. “Our customers require best in class solutions for their diverse workflow and as part of an interconnected ecosystem we are committed to working with partners like Proscia to help drive digital pathology forward.”
*Proscia software is not intended for primary diagnostic use
“Proscia’s new clinical solutions are exciting, as they give us the flexibility to adopt digital pathology in phases and set us on a course to incorporate Proscia’s AI-based computational pathology applications,” said Dr. Nicolas Cacciabeve, Managing Director of Advanced Pathology Associates, a 15-pathologist independent practice providing service to seven hospitals and an anatomic pathology reference laboratory in the Rockville, Maryland area. “The application of digital pathology in our practice will transform both the economics and profits of our practice and most importantly improve patient outcomes.”
Proscia’s newly released clinical offering is the next major step in the company’s evolution, focusing on improving clinical workflow and providing pathologists with powerful software and applications for a wide range of non-primary diagnostic clinical uses in a case-centric workflow.*
Commercial and medical facility users of Proscia’s new clinical offering gain access to a broad range of capabilities within a single, unified, platform, including:
• Modular adoption of digital pathology, for those clients who choose to incrementally adopt digital pathology
• An online, role-based consultation portal
• Automated quantitative immunohistochemistry (IHC)
• Image analysis
• Image and case management with configurable workflows
• HIPAA compliant infrastructure
• LIS integration
• Flexible deployment options in the cloud or on-prem
• Vendor-agnostic scanner support
“Labs have been adopting digital solutions incrementally over the past five to ten years, furthering the regulatory and economic incentives to go digital,” said David West Jr., co-founder and chief executive officer of Proscia. “Proscia’s clinical offering is released at a time of growing enthusiasm around clinical applications for digital pathology. Our new release provides our customers with new opportunities to expand the reach and expertise of their existing practices while building a launch-pad for the next generation of precision medicine and analytic tools for pathology automation and augmentation through computational pathology.”
Computational pathology offers an opportunity to combine the Whole Slide Images of digital pathology with other sources of data – such as LIMS, EMR, laboratory data (“-omics”), and radiology images, and then apply AI-based algorithms to provide pathologists with a more complete, computer-assisted view of the disease processes present in a tissue sample. Such algorithms can identify complex histological patterns like tumors, classify cancer subtypes, and even predict outcomes with a high degree of accuracy. These building block capabilities can be deployed in pathology workflows for precision screening, automated triaging, and used as image-based assays as corollaries or in complement with their molecular counterparts.
Join Proscia’s webinar, “Pathology is going digital. Is your lab ready?”, on October 19th to learn more.
Proscia’s new computational pathology platform has caught the imagination of a broad ecosystem as a best-in-class solution to both augment the work of pathologists and dramatically improve patient outcomes.
NVIDIA is another technology company taking notice of the impact that Proscia is having on pathology. “AI is changing the healthcare landscape and pathology is one area that could benefit greatly,” said Abdul Hamid Halabi, Global Business Development Lead, Healthcare & Life Sciences at NVIDIA. “Proscia is building a leading platform to leverage AI for pathology with the goal of not only helping physicians become more efficient, but also to give them the ability to innovate beyond the limits of current pathology tools.”
“Pathology is at an inflection point and the shift to digital is now a strategic initiative for anatomic pathology labs,” said Patrick Myles, CEO at Huron Digital Pathology. “Our customers require best in class solutions for their diverse workflow and as part of an interconnected ecosystem we are committed to working with partners like Proscia to help drive digital pathology forward.”
*Proscia software is not intended for primary diagnostic use
